Companies

Novo Nordisk Stock Plummets After New Weight-Loss Drug Falls Short Against Rival

The test drug, CagriSema, failed to match Eli Lilly’s Zepbound after an 84-week trial, the company said.
Novo Nordisk Stock Plummets After New Weight-Loss Drug Falls Short Against Rival
The logo of Danish pharmaceutical company Novo Nordisk is pictured at their headquarters in Bagsvaerd, Denmark, on Feb. 1, 2017. Liselotte Sabroe/Scanpix Denmark/AFP via Getty Images
Mary Prenon
Mary Prenon
Freelance Reporter
|Updated:
0:00
Stock prices for Denmark-based Novo Nordisk dropped by more than 15 percent on Feb. 23 after the global healthcare firm announced disappointing results from a clinical trial of CagriSema.

Known for its Ozempic injectable medication for treating diabetes and obesity, Novo Nordisk’s newest pharmaceutical just completed its phase 3 trial, called REDEFINE 4, an 84-week trial test of CagriSema, a combination of cagrilintide 2.4 mg and semaglutide 2.4 mg injectable.

Mary Prenon
Mary Prenon
Freelance Reporter
Mary T. Prenon covers real estate and business. She has been a writer and reporter for over 25 years with various print and broadcast media in New York.